This was the stock's third consecutive day of gains.
Regeneron is also embroiled in a securities fraud class action lawsuit stemming from a significant stock price drop on October 31, 2024. Shares plunged $84.59 that day, wiping out approximately $9 ...
Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.
On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...
Hosted on MSN8h
Biogen Stock Is Mutating Into a Value PlayBiogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from ...
Medpage Today on MSN16h
Semaglutide Tied to Small Risk of Potentially Blinding Eye ConditionThe use of semaglutide (Ozempic) was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in ...
During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback